NovalGen
London, GB · Founded 2019 · 11 employees on LinkedIn · 2 known investors
Find your way into NovalGen
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, autoimmune, haematological, and metabolic disorders using its proprietary AutoRegulation platform technology.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- NOVALGEN LIMITED
- Company number
- 11621264
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 14 Oct 2018
- Registered office
- Argyle House Level 3 Northside, Joel Street, Northwood Hills, Middlesex, HA6 1NW
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- IMMUNOCURE LIMITED (2018–2018)
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 13 Oct 2025 · next due 27 Oct 2026
Current officers · 7
- Scott Clarke — director, appointed 9 Dec 2022
- Samit Govindji Hathi — director, appointed 7 Jan 2019
- Amit Chunilal Nathwani — director, appointed 6 Jan 2020
- Michael Owen — director, appointed 3 Jan 2023
- Bharat Kumar Hirji Thakrar — director, appointed 7 Jan 2019
- David Charles Venables — director, appointed 24 Mar 2023
- Ucltf Corporate Directors Ltd — corporate director, appointed 15 Feb 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does NovalGen do?
- NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, autoimmune, haematological, and metabolic disorders using its proprietary AutoRegulation platform technology.
- Who are NovalGen's investors?
- NovalGen's investors include AlbionVC, UCL Technology Fund.
- Where is NovalGen headquartered?
- NovalGen is headquartered in London, GB.